Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.37 |
| ▸ | DRD3 | P35462 | 6/20 | 0.37 |
| ▸ | HTR1D | P28221 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015000 | 0.89 | DRD2 (0.38) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL18069445 | 0.87 | DRD2 (0.33) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL19449967 | 0.86 | DRD2 (0.34) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL21878981 | 0.85 | DRD2 (0.34) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL20026787 | 0.85 | DRD2 (0.34) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL10512980 | 0.85 | DRD2 (0.36) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL22748433 | 0.84 | DRD2 (0.36) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL22748394 | 0.84 | DRD2 (0.36) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL12811147 | 0.84 | DRD2 (0.33) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL17731215 | 0.83 | ALDH1A1 (0.35) | DRD2DRD3HTR1DDRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815857-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-2158206-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155016-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | DRD2 2643/4885DRD3 3112/4885HTR1D 1115/4885 |
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, GUCY1B1 | DRD2 3221/4885DRD3 3778/4885HTR1D 1209/4885 |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | DRD2 4838/4885DRD3 4825/4885HTR1D 4830/4885 |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | DRD2 3995/4885DRD3 3875/4885HTR1D 3280/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | DRD2 2643/4885DRD3 3112/4885HTR1D 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.